Sanofi Defends Beyfortus Amid Emerging Maternal RSV Vaccine Threat

The French firm used a vaccines investor event to tout its respiratory syncytial virus prophylactic, Beyfortus, citing real-world data as well as a predictive model following recent questions about its utility in the face of advancing maternal vaccines.